NewEdge Advisors LLC Sells 2,491 Shares of Danaher Corporation $DHR

Key Points

• NewEdge Advisors LLC reduced its holdings in Danaher Corporation by 4.4%, now owning 54,299 shares valued at approximately $11.13 million.
• Despite reductions from some investors, Vanguard Group Inc. and others increased their stakes in Danaher, indicating continued institutional interest in the stock.
• Danaher reported better-than-expected earnings of $1.80 EPS, beating estimates and reflecting a 3.4% year-over-year revenue growth.

NewEdge Advisors LLC decreased its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 4.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,299 shares of the conglomerate's stock after selling 2,491 shares during the quarter. NewEdge Advisors LLC's holdings in Danaher were worth $11,131,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MGO One Seven LLC lifted its stake in Danaher by 485.7% in the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after buying an additional 20,813 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in Danaher in the first quarter valued at approximately $539,000. Horizon Financial Services LLC lifted its stake in Danaher by 20,400.0% in the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc lifted its stake in Danaher by 6.1% in the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after buying an additional 2,009 shares in the last quarter. Finally, EFG Asset Management Americas Corp. lifted its stake in Danaher by 13.1% in the first quarter. EFG Asset Management Americas Corp. now owns 36,080 shares of the conglomerate's stock valued at $7,396,000 after buying an additional 4,191 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DHR shares. Evercore ISI cut their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday, September 2nd. Guggenheim restated a "buy" rating and set a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Barclays reiterated an "overweight" rating and issued a $225.00 price target (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Robert W. Baird lifted their price target on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research note on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 11.10% of the stock is owned by insiders.

Danaher Stock Performance

NYSE DHR traded up $2.71 on Thursday, hitting $195.30. 2,169,990 shares of the stock were exchanged, compared to its average volume of 4,132,310. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The business's fifty day moving average is $201.62 and its 200 day moving average is $199.15. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a market capitalization of $139.85 billion, a PE ratio of 41.55, a P/E/G ratio of 2.71 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the firm posted $1.72 earnings per share. The company's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.